August 17: An analysis of productivity costs associated with metastatic breast cancer found that metastatic breast cancer creates a high economic burden through lost productivity, especially among women considered to be midlife. Read more on Cancer Network HERE.
August 18: The results of an online questionnaire of breast cancer survivors in the US suggest that nearly half of patients experienced delays in care during the early weeks of the COVID-19 pandemic. Read the full story HERE is Science Daily.
August 19: Researchers at Duke University have developed a vaccine that targets HER2, a protein found on about 20% of breast cancers. The vaccine has so far produced promising results when paired with existing drug therapies. The vaccine is currently in Phase 2 trials. Read more in The Chronicle HERE.
August 23: A recent study indicates that risks of all-cause mortality and breast cancer-specific mortality decreased when postmenopausal female patients with invasive breast cancer followed a more anti-inflammatory diet after their diagnosis. Read the full story in AJMC HERE.
August 28: According to data from Phase I clinical trials, a new breast cancer drug developed by researchers at the University of Illinois Chicago can potentially stop progression of estrogen receptor-positive (ER-positive) breast cancer without toxicity. Read the full article in BioSpace HERE.
August 31: A recent study indicates that honeybee venom rapidly destroyed triple-negative breast cancer and HER2-enriched breast cancer cells. Read more in Science Daily HERE.